- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05822076
Influence of Thoracic Paravertebral Block on Cardiac Repolarization
Evaluation of Influence of Thoracic Paravertebral Block on Cardiac Repolarization
Aim of the study is to determine the presence and direction of electrocardiographical changes of cardiac repolarization after thoracic paravertebral block, depending on block laterality.
Injection of local anaesthetic into paravertebral space (paravertebral block, PVB) temporarily impairs transmission in nerve fibers in proximity of the deposition site. In case of PVB covering the rami of upper thoracic spinal nerves, among the others thoracic sympathetic cardiac nerves are blocked, possibly affecting action potential time of heart, especially the repolarization, and the related electrocardiographic phenomena.
The risk of life-threatening polymorphic ventricular tachycardia (torsade des pointes, TdP) is associated with certain electrocardiographical symptoms, like QT interval prolongation and increased transmural repolarization dispersion (TDR). Determining the presence and direction of cardiac repolarization changes after a thoracic PVB will allow to conclude about its impact on TdP risk: protective or, contrary, arrhythmogenic.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After obtaining written informed consent, 60 women above 18 years of age scheduled to elective breast surgery in combined regional and general anaesthesia will be enrolled to study, divided in two groups depending of the side of operation. Participants will undergo the ultrasound-guided paravertebral block with single injection of 0.5% ropivacaine (0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients) without adjuvants. Before injection (T0) and after confirmation of sufficient sensory block area covering 1st to 4th thoracic dermatomes (T1), 12-lead electrocardiogram (ECG) will be recorded using a Holter device. First examination of sensory block distribution will be performed 6 minutes after injection, with subsequent examinations if needed - every minute up to 15 minutes. No sedative premedication, general anaesthesia induction or additional medications (except of neutral saline maintaining intravenous access) will be administered until completions of ECG recording. Both T0 and T1 electrocardiogram will be preceded by rest in supine position for at least 5 minutes, without any medical procedures other than monitoring. Cases with baseline QT or corrected QT longer than 440 milliseconds (ms) will be excluded from study.
The QT interval and TDR (measured as time in milliseconds between ECG T wave peak [Tpeak] and end [Tend]) values obtained from baseline and post-blockade electrocardiograms will be statistically analyzed and compared between study groups.
The minimum sample size was calculated as 26 cases per study group, assuming a change in corrected QT of 20 milliseconds from the baseline value, with a significance level of p=0.05 and a test power of 0.9. Sample size was expanded to 30 cases per group, due to anticipated exclusions at the stage of intervention or data analysis.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Gdańsk, Poland, 80-214
- Medical University of Gdańsk - Departament of Anesthesiology and Intensive Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- woman above 18 years of age, legally able of giving informed consent
- participants previously qualified for elective breast surgery due to neoplasm, with or without axillary node dissection
- physical status corresponding to class I or II in American Society of Anaesthesiologist classification
Exclusion Criteria:
- lack of consent to participation or to regional anaesthesia for planned surgery
- bilateral operation planned
- symptomatic circulatory disease at the time of qualification, artificial heart pacemaker presence, positive history of arrythmia
- allergy to amide local anaesthetics
- use of medications with "known" or "possible" potential of QT prolongation, according to Arizona Center for Education and Research on Therapeutics [AZCERT] Inc. list, in 5 days preceding the intervention
- severe deformation of thoracic spine
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
L - paravertebral block left
30 woman above 18 years of age qualified for elective breast surgery on the left side of the body
|
Paravertebral block at the level of 3rd thoracic intervertebral space on the left side.
0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
|
P - paravertebral block right
30 woman above 18 years of age qualified for elective breast surgery on the right side of the body
|
Paravertebral block at the level of 3rd thoracic intervertebral space on the right side.
0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QT interval
Time Frame: during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))
|
difference in milliseconds of QT interval between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]
|
during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))
|
Corrected QT interval
Time Frame: during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))
|
difference in milliseconds of QT interval corrected [according to Bazett, Framingham, Fredericia formulas] between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]
|
during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))
|
Tpeak-Tend
Time Frame: during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))
|
difference in milliseconds of Tpeak-Tend time between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]
|
during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Radosław Owczuk, MD, PhD, Medical University of Gdansk
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NKBBN/948/2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on QT Interval
-
Lexicon PharmaceuticalsCompleted
-
Indiana UniversityPurdue UniversityCompletedQT Interval ProlongationUnited States
-
Peking University Third HospitalUnknown
-
Duzce UniversityCompletedQt Interval, Variation inTurkey
-
University of SunderlandSheffield Hallam University; Newcastle University; Teesside UniversitySuspendedQt Interval, Variation inUnited Kingdom
-
Samsung Medical CenterCompletedQt Interval, Variation inKorea, Republic of
-
NobelpharmaCompleted
-
Poxel SACompletedQt Interval, Variation inUnited Kingdom
-
WockhardtCompletedQt Interval, Variation inUnited States
-
University of California, Los AngelesNational Institute of Nursing Research (NINR); Columbia University; University... and other collaboratorsCompletedCardiac Transplant Rejection | Qt Interval, Variation inUnited States
Clinical Trials on Paravertebral block (ropivacaine) left
-
Larissa University HospitalUnknownBreast Surgery | Autonomic Nervous System | Thoracic Paravertebral Block | HRVGreece
-
China Medical University, ChinaWithdrawn
-
Makassed General HospitalRecruiting
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalCompletedVideo-assisted Thoracoscopic Surgery | Postoperative Analgesia | Thoracic Paravertebral BlockTurkey
-
Ospedale Regionale Bellinzona e ValliRecruitingOther Acute Postoperative PainSwitzerland
-
Huazhong University of Science and TechnologyRecruitingPain, Acute | Nerve Block | Thoracic AnesthesiaChina
-
Assiut UniversityCompletedRenal Stone | Percutaneous | NephrolithotomyEgypt